PREVENTION OF GRAM-NEGATIVE SHOCK AND DEATH IN SURGICAL PATIENTS BY ANTIBODY TO ENDOTOXIN CORE GLYCOLIPID
- 1 July 1985
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 326 (8446), 59-63
- https://doi.org/10.1016/s0140-6736(85)90176-x
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- ANTI-LIPOPOLYSACCHARIDE IMMUNOTHERAPY FOR GRAM-NEGATIVE SEPTICAEMIAThe Lancet, 1984
- ANTI-LIPOPOLYSACCHARIDE IMMUNOTHERAPY IN MANAGEMENT OF SEPTIC SHOCK OF OBSTETRIC AND GYNAECOLOGICAL ORIGINThe Lancet, 1984
- Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core.JCI Insight, 1983
- Treatment of Gram-Negative Bacteremia and Shock with Human Antiserum to a MutantEscherichia coliNew England Journal of Medicine, 1982
- Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide.JCI Insight, 1982
- Neutralization of meningococcal endotoxin by antibody to core glycolipid.The Journal of Experimental Medicine, 1978
- Functional role of antibody against "core" glycolipid of Enterobacteriaceae.JCI Insight, 1975
- Human Antiserum for Prevention of the Local Shwartzman Reaction and Death from Bacterial LipopolysaccharidesJCI Insight, 1973
- Treatment and Prevention of Intravascular Coagulation with Antiserum to EndotoxinThe Journal of Infectious Diseases, 1973
- PROTECTION AGAINST LETHALITY OF E. COLI ENDOTOXIN WITH “O” ANTISERUM*Annals of the New York Academy of Sciences, 1966